Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III colon cancer with separate analy...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2017-05, Vol.109 (5), p.djw272
Hauptverfasser:	Taieb, Julien, Le Malicot, Karine, Shi, Qian, Penault-Llorca, Frédérique, Bouché, Olivier, Tabernero, Josep, Mini, Enrico, Goldberg, Richard M, Folprecht, Gunnar, Luc Van Laethem, Jean, Sargent, Daniel J, Alberts, Steven R, Emile, Jean Francois, Laurent Puig, Pierre, Sinicrope, Frank A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - genetics Adenocarcinoma - secondary Adenocarcinoma - therapy Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cetuximab - administration & dosage Chemotherapy, Adjuvant Colectomy Colonic Neoplasms - genetics Colonic Neoplasms - pathology Colonic Neoplasms - therapy DNA Mismatch Repair Female Fluorouracil - therapeutic use Humans Leucovorin - therapeutic use Male Microsatellite Instability Middle Aged Mutation Neoplasm Recurrence, Local - genetics Neoplasm Staging Organoplatinum Compounds - therapeutic use Prognosis Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) - genetics Survival Rate Time Factors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!